Literature DB >> 20524153

Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

George R Thompson1, Nathan P Wiederhold.   

Abstract

Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20524153     DOI： 10.1007/s11046-010-9324-3

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   2.574


  12 in total

Review 1.  A higher-level phylogenetic classification of the Fungi.

Authors:  David S Hibbett; Manfred Binder; Joseph F Bischoff; Meredith Blackwell; Paul F Cannon; Ove E Eriksson; Sabine Huhndorf; Timothy James; Paul M Kirk; Robert Lücking; H Thorsten Lumbsch; François Lutzoni; P Brandon Matheny; David J McLaughlin; Martha J Powell; Scott Redhead; Conrad L Schoch; Joseph W Spatafora; Joost A Stalpers; Rytas Vilgalys; M Catherine Aime; André Aptroot; Robert Bauer; Dominik Begerow; Gerald L Benny; Lisa A Castlebury; Pedro W Crous; Yu-Cheng Dai; Walter Gams; David M Geiser; Gareth W Griffith; Cécile Gueidan; David L Hawksworth; Geir Hestmark; Kentaro Hosaka; Richard A Humber; Kevin D Hyde; Joseph E Ironside; Urmas Kõljalg; Cletus P Kurtzman; Karl-Henrik Larsson; Robert Lichtwardt; Joyce Longcore; Jolanta Miadlikowska; Andrew Miller; Jean-Marc Moncalvo; Sharon Mozley-Standridge; Franz Oberwinkler; Erast Parmasto; Valérie Reeb; Jack D Rogers; Claude Roux; Leif Ryvarden; José Paulo Sampaio; Arthur Schüssler; Junta Sugiyama; R Greg Thorn; Leif Tibell; Wendy A Untereiner; Christopher Walker; Zheng Wang; Alex Weir; Michael Weiss; Merlin M White; Katarina Winka; Yi-Jian Yao; Ning Zhang
Journal:  Mycol Res       Date:  2007-03-13

2.  Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Nathan P Wiederhold; Annette W Fothergill; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 3.  Antifungal activity against Scedosporium species and novel assays to assess antifungal pharmacodynamics against filamentous fungi.

Authors:  Nathan P Wiederhold; Russell E Lewis
Journal:  Med Mycol       Date:  2009-06       Impact factor: 4.076

4.  In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

Authors:  Maria-Teresa Illnait-Zaragozi; Gerardo F Martínez; Ilse Curfs-Breuker; Carlos M Fernández; Teun Boekhout; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

5.  Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

6.  In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.

Authors:  Gloria M González
Journal:  Med Mycol       Date:  2008-12-18       Impact factor: 4.076

7.  Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Annette W Fothergill; Nathan P Wiederhold; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

8.  In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Susanne Perkhofer; Veronika Lechner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

9.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Authors:  Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Journal:  J Antimicrob Chemother       Date:  2006-10-27       Impact factor: 5.758

10.  In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.

Authors:  Jesús Guinea; Teresa Peláez; Sandra Recio; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.938
View more
  37 in total

1.  Eighty Years of Mycopathologia: A Retrospective Analysis of Progress Made in Understanding Human and Animal Fungal Pathogens.

Authors:  Vishnu Chaturvedi; Jean-Philippe Bouchara; Ferry Hagen; Ana Alastruey-Izquierdo; Hamid Badali; Anamelia Lorenzetti Bocca; Jose F Cano-Lira; Cunwei Cao; Sudha Chaturvedi; Sanjay H Chotirmall; Anne D van Diepeningen; Jean-Pierre Gangneux; Jesus Guinea; Sybren de Hoog; Macit Ilkit; Rui Kano; Weida Liu; Nilce M Martinez-Rossi; Marcia de Souza Carvalho Melhem; Mario Augusto Ono; Yuping Ran; Stephane Ranque; Celia Maria de Almeida Soares; Takashi Sugita; Philip A Thomas; Anna Vecchiarelli; Nancy L Wengenack; Patrick C Y Woo; Jianping Xu; Rosely M Zancope-Oliveira
Journal:  Mycopathologia       Date:  2018-11-30       Impact factor: 2.574

Review 2.  Isavuconazonium: first global approval.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

3.  Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.

Authors:  Mariana Castanheira; Shawn A Messer; Paul R Rhomberg; Rachel R Dietrich; Ronald N Jones; Michael A Pfaller
Journal:  Mycopathologia       Date:  2014-06-21       Impact factor: 2.574

4.  Comparison of the in vitro activities of newer triazoles and established antifungal agents against Trichophyton rubrum.

Authors:  Shuwen Deng; Chao Zhang; Seyedmojtaba Seyedmousavi; Shuang Zhu; Xin Tan; Yiyang Wen; Xin Huang; Wenzhi Lei; Zhaojing Zhou; Wenjie Fang; Shuaishuai Shen; Danqi Deng; Weihua Pan; Wanqing Liao
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

Review 5.  Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions.

Authors:  Dimitrios P Kontoyiannis; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

Review 6.  New facets of antifungal therapy.

Authors:  Ya-Lin Chang; Shang-Jie Yu; Joseph Heitman; Melanie Wellington; Ying-Lien Chen
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

7.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

8.  Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.

Authors:  A Espinel-Ingroff; A Chowdhary; G M Gonzalez; J Guinea; F Hagen; J F Meis; G R Thompson; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

9.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

10.  Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.

Authors:  A Espinel-Ingroff; A Chowdhary; G M Gonzalez; C Lass-Flörl; E Martin-Mazuelos; J Meis; T Peláez; M A Pfaller; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.